Loading…
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $140M | $-361M | $-80M | $-360M | -6.5% | 120.0% | -78.8% |
| 2024 | $64M | $-394M | $-377M | $-356M | -51.4% | -83.2% | 184.3% |
| 2023 | $378M | $-156M | $-133M | $-183M | -13.5% | 520.0% | -54.2% |
| 2022 | $61M | $-316M | $-289M | $-26M | -39.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 60.92 | 377.71 | 63.52 | 139.74 |
| Operating Revenue | - | 60.92 | 377.71 | 63.52 | 139.74 |
| Operating Expense | - | 399.40 | 554.19 | 479.09 | 523.44 |
| Research And Development | - | 311.59 | 437.38 | 367.56 | 409.62 |
| Selling General And Administration | - | 87.80 | 116.81 | 111.52 | 113.82 |
| Total Expenses | - | 399.40 | 554.19 | 479.09 | 523.44 |
| Operating Income | - | -338.48 | -176.48 | -415.57 | -383.69 |
| Total Operating Income As Reported | - | -338.48 | -176.48 | -415.57 | -383.69 |
| EBITDA | - | -315.90 | -156.47 | -393.64 | -361.40 |
| Normalized EBITDA | - | -378.91 | -155.12 | -383.41 | -366.22 |
| EBIT | - | -338.48 | -176.48 | -415.57 | -383.69 |
| Net Interest Income | - | 15.30 | 46.68 | 49.09 | 43.73 |
| Other Income Expense | - | 63 | -1.35 | -10.23 | 259.97 |
| Net Non Operating Interest Income Expense | - | 15.30 | 46.68 | 49.09 | 43.73 |
| Pretax Income | - | -260.18 | -131.16 | -376.70 | -79.99 |
| Tax Provision | - | 3.41 | 1.37 | 0.04 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 13.23 | -0.28 | 0 | 0 |
| Net Income Continuous Operations | - | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income From Continuing And Discontinued Operation | - | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income From Continuing Operation Net Minority Interest | - | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income | - | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income Common Stockholders | - | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income Including Noncontrolling Interests | - | -289.09 | -132.53 | -376.74 | -79.99 |
| Normalized Income | - | -338.86 | -131.46 | -366.51 | -84.81 |
| Diluted NI Availto Com Stockholders | - | -289.09 | -132.53 | -376.74 | -79.99 |
| Basic Average Shares | - | 70.02 | 77.15 | 82.31 | 98.91 |
| Diluted Average Shares | - | 70.02 | 77.15 | 82.31 | 98.91 |
| Reconciled Depreciation | - | 22.58 | 20.01 | 21.92 | 22.29 |
| Total Unusual Items | - | 63 | -1.35 | -10.23 | 4.82 |
| Total Unusual Items Excluding Goodwill | - | 63 | -1.35 | -10.23 | 4.82 |
| Earnings From Equity Interest Net Of Tax | 0 | -25.50 | 0 | 0 | - |
| Special Income Charges | - | 18.90 | 9.74 | 1.59 | 0.18 |
| Restructuring And Mergern Acquisition | - | -18.90 | -9.74 | -1.59 | -0.18 |
| Gain On Sale Of Security | - | 44.10 | -11.09 | -11.82 | 4.64 |
| General And Administrative Expense | - | 87.80 | 116.81 | 111.52 | 113.82 |
| Other Gand A | - | 87.80 | 116.81 | 111.52 | 113.82 |
| Total Other Finance Cost | - | -15.30 | -46.68 | -49.09 | -43.73 |
| Earnings From Equity Interest | 17.69 | - | 0 | 0 | 255.15 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Beam Therapeutics Inc.this co. | BEAM | $3.4B | -42.24 | 2.73 | -6.5% | -8.96 |
| Crinetics Pharmaceuticals, Inc. | CRNX | $3.7B | -7.85 | 3.68 | -46.9% | -7.02 |
| iRhythm Holdings, Inc. | IRTC | $3.5B | -79.19 | 23.10 | -29.2% | -1014.62 |
| Tango Therapeutics, Inc. | TNGX | $3.2B | -31.54 | 9.26 | -29.3% | -28.67 |
| Denali Therapeutics Inc. | DNLI | $3.2B |
| - |
| - |
| - |
| - |
| - |
| - |
| -6.24 |
| 3.15 |
| -50.6% |
| -5.60 |
| Haemonetics Corporation | HAE | $3.2B | 32.62 | 3.99 | 12.2% | 15.47 |
| Relay Therapeutics, Inc. | RLAY | $3.2B | -11.46 | 5.59 | -48.8% | -10.42 |
| Option Care Health, Inc. | OPCH | $3.2B | 15.18 | 2.38 | 15.6% | 10.27 |
| Alignment Healthcare, Inc. | ALHC | $3.1B | - | 17.38 | -0.4% | 62.69 |
| Peer Median | - | -7.85 | 4.79 | -29.3% | -6.31 | |